Trial intelligence / Profile preview

Phase II randomized double-blind active-controlled study of oral BG2109 during controlled ovarian hyperstimulation in women undergoing ART

CTR20222174Phase 2Terminated

Sponsor
Kissei Pharmaceutical Co., Ltd.
Start
Sep 2022
Modality
Small Molecules
Countries
1
01

Overview

A Phase 2 trial of linzagolix in infertility, sponsored by Kissei Pharmaceutical Co., Ltd.. Started Sep 2022; status: terminated.

02

Drugs

linzagolix
03

Conditions

infertility

Beyond the preview

Go deeper on CTR20222174.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on CTR20222174.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call